• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Special Purpose Acquisition Companies: The Briscoe Law Firm, PLLC Announce Investigation into the following SPACs

    3/8/23 5:30:00 PM ET
    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Computer Software: Prepackaged Software
    Technology
    Diversified Commercial Services
    Miscellaneous
    Get the next $BBAI alert in real time by email

    Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm The Briscoe Law Firm, PLLC are investigating potential violation of laws in connection with the following special purpose acquisition companies ("SPACs"): BigBear.ai Holdings, Inc. f/k/a GigCapital4 Inc. (NYSE:BBAI), Senti Biosciences, Inc. f/k/a Dynamics Special Purpose Corp (NASDAQGM:SNTI), Tango Therapeutics, Inc. f/k/a BCTG Acquisition Corp (NASDAQGM:TNGX), and Boxed, Inc. f/k/a Seven Oaks Acquisition Corp (NYSE:BOXD).

    If you are an affected investor, and you want to learn more about this investigation, please contact Willie Briscoe at The Briscoe Law Firm, PLLC, (972) 521-6868, or via email at [email protected]. There is no cost or fee to you.

    The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 23 years of experience in complex securities litigation and transactional matters.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005867/en/

    Get the next $BBAI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BBAI
    $BOXD
    $SNTI
    $TNGX

    CompanyDatePrice TargetRatingAnalyst
    Senti Biosciences Inc.
    $SNTI
    6/6/2025$5.00Buy
    Laidlaw
    BigBear.ai Inc.
    $BBAI
    3/7/2025$2.50 → $4.00Outperform → Market Perform
    Northland Capital
    BigBear.ai Inc.
    $BBAI
    12/30/2024$3.00 → $7.00Buy
    H.C. Wainwright
    Tango Therapeutics Inc.
    $TNGX
    7/17/2024$19.00Buy
    Jefferies
    Tango Therapeutics Inc.
    $TNGX
    4/4/2024Overweight
    Cantor Fitzgerald
    Tango Therapeutics Inc.
    $TNGX
    2/12/2024$18.00Overweight
    Piper Sandler
    BigBear.ai Inc.
    $BBAI
    1/9/2024$3.00Overweight
    Cantor Fitzgerald
    Tango Therapeutics Inc.
    $TNGX
    12/8/2023$16.00Buy
    B. Riley Securities
    More analyst ratings

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BigBear.ai Demonstrates AI-Driven Forecasting and Sentiment Analysis at Project Convergence - Capstone 5 Experiment

      BigBear.ai (NYSE:BBAI), a leading provider of mission-ready AI for defense and national security, today announced its participation in Project Convergence - Capstone 5 (PC-C5). PC-C5 is a combined joint and multinational experiment allowing partners and allies across Australia, Canada, France, Japan, New Zealand, United Kingdom, and all branches of the United States military to integrate resources and technologies in support of defense transformation efforts for future warfighters. The PC-C5 experiment presented opportunities for multinational forces to test Next Generation Command Control (NGC2) systems using relevant AI models. BigBear.ai's Virtual Anticipation Network (VANE) platform p

      7/1/25 9:15:00 AM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • Senti Bio Participates in Nasdaq Amplify Spotlight Series

      Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer recently participated in Nasdaq's Amplify Spotlight Series. As part of the segment, Dr. Lu provided a corporate overview and highlighted how Senti is leveraging its proprietary Gene Circuit platform to develop next-generation cell and gene therapies for the treatment of challenging liquid and solid tumor indications. T

      6/30/25 9:15:41 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung Cancer

      BOSTON, June 27, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering the next generation of precision cancer medicines, today announced that the first patient has been dosed in the Phase 1/2 trial of TNG462 and Revolution Medicines' daraxonrasib (RAS(ON) multi-selective inhibitor) or zoldonrasib (RAS(ON) G12D-selective inhibitor) in patients with MTAP-deleted and RAS mutant metastatic pancreatic or lung cancer. "Almost all MTAP-del pancreatic and approximately 30% of lung cancers have a co-occurring RAS mutation, and preclinical data show strong combination activity of TNG462 with either daraxonrasib or zoldo

      6/27/25 7:00:00 AM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Laidlaw initiated coverage on Senti Bio with a new price target

      Laidlaw initiated coverage of Senti Bio with a rating of Buy and set a new price target of $5.00

      6/6/25 8:36:59 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • BigBear.ai downgraded by Northland Capital with a new price target

      Northland Capital downgraded BigBear.ai from Outperform to Market Perform and set a new price target of $4.00 from $2.50 previously

      3/7/25 8:22:38 AM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • H.C. Wainwright reiterated coverage on BigBear.ai with a new price target

      H.C. Wainwright reiterated coverage of BigBear.ai with a rating of Buy and set a new price target of $7.00 from $3.00 previously

      12/30/24 7:16:05 AM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    SEC Filings

    See more
    • Senti Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Senti Biosciences, Inc. (0001854270) (Filer)

      6/30/25 4:02:07 PM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Senti Biosciences, Inc. (0001854270) (Filer)

      6/18/25 7:05:30 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SCHEDULE 13G filed by Tango Therapeutics Inc.

      SCHEDULE 13G - Tango Therapeutics, Inc. (0001819133) (Subject)

      6/13/25 5:25:29 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rothenberg Mace bought $74,000 worth of shares (20,000 units at $3.70), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

      4 - Tango Therapeutics, Inc. (0001819133) (Issuer)

      11/18/24 7:20:03 PM ET
      $TNGX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Braden Pamela Joyce bought $209,999 worth of shares (140,939 units at $1.49), increasing direct ownership by 46% to 446,396 units (SEC Form 4)

      4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

      6/6/24 5:52:55 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • Braden Pamela Joyce bought $96,048 worth of shares (50,025 units at $1.92), increasing direct ownership by 20% to 305,457 units (SEC Form 4)

      4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

      12/21/23 5:21:13 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Ricker Sean Raymond covered exercise/tax liability with 6,524 shares, decreasing direct ownership by 2% to 308,325 units (SEC Form 4)

      4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

      7/3/25 4:39:10 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • General Counsel and Secretary Blankenship Carolyn covered exercise/tax liability with 5,945 shares, decreasing direct ownership by 0.89% to 658,925 units (SEC Form 4)

      4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

      7/3/25 4:35:20 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • Chief Executive Officer Mcaleenan Kevin covered exercise/tax liability with 3,113 shares, decreasing direct ownership by 0.25% to 1,221,780 units (SEC Form 4)

      4 - BigBear.ai Holdings, Inc. (0001836981) (Issuer)

      7/3/25 4:33:40 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Leadership Updates

    Live Leadership Updates

    See more
    • BigBear.ai Announces CFO Transition

      BigBear.ai (NYSE:BBAI) announced today, June 6, 2025, that Sean Ricker has been appointed interim Chief Financial Officer, effective immediately, succeeding Julie Peffer as Chief Financial Officer. "I am pleased to announce the interim appointment of Sean Ricker as our Chief Financial Officer. Sean has a wealth of experience at BigBear.ai, where he most recently held the role of Chief Accounting Officer, prior to which he was Corporate Controller," said Kevin McAleenan, Chief Executive Officer. "Sean joined us shortly before BigBear.ai became a public company and has been a key leader in getting us to this stage in our growth. Given his familiarity with the business, stakeholders, and o

      6/6/25 4:44:00 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • Senti Bio Bolsters Scientific Advisory Board with Appointment of James B. Trager, Ph.D.

      Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from "bench to bedside" and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced the appointment of James B. Trager, Ph.D. to its Scientific Advisor

      4/10/25 8:45:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Catalyze Partners Appoints Raanan Horowitz to Board of Advisors

      Catalyze Partners has appointed Raanan Horowitz, former CEO of Elbit Systems of America, to its Board of Advisors. With over 30 years of leadership experience across the defense, commercial aviation, and healthcare sectors, Horowitz has a proven track record of driving growth and overseeing strategic acquisitions. Drawing from his extensive experience in scaling companies and navigating complex markets, Horowitz will help Catalyze further develop its portfolio of innovative technology-driven companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203110969/en/Catalyze Partners adds Raanan Horowitz to its Board of Advisors.

      12/3/24 10:00:00 AM ET
      $BBAI
      $GIA
      Computer Software: Prepackaged Software
      Technology
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Financials

    Live finance-specific insights

    See more
    • Senti Bio Participates in Nasdaq Amplify Spotlight Series

      Access the segment here SOUTH SAN FRANCISCO, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D. Co-Founder and Chief Executive Officer recently participated in Nasdaq's Amplify Spotlight Series. As part of the segment, Dr. Lu provided a corporate overview and highlighted how Senti is leveraging its proprietary Gene Circuit platform to develop next-generation cell and gene therapies for the treatment of challenging liquid and solid tumor indications. T

      6/30/25 9:15:41 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio to Present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference

      SOUTH SAN FRANCISCO, Calif., June 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will present at the 2025 Synthetic Biology: Engineering, Evolution, & Design (SEED) Conference being held June 23-26, 2025 in Houston, TX. Details of the presentation are as follows: Session: Building with BiologyTitle: Solving the Grand Challenge of Tumor-Specific Therapies with Logic-Gated CellsPresenter: Timothy Lu, MD, PhD, Co-Founder and CEO of Senti BiosciencesDate and Time: Tuesday, June 24, 20

      6/24/25 8:45:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia

      Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients experiencing relapse or death within 12 months2 Management releases Virtual Investor "What This Means" segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (NASDAQ:SNTI) ("Senti Bio" or the "Company"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-

      6/18/25 7:00:00 AM ET
      $SNTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BBAI
    $BOXD
    $SNTI
    $TNGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

      SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

      12/16/24 9:09:02 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

      SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

      12/12/24 4:17:36 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology
    • Amendment: SEC Form SC 13D/A filed by BigBear.ai Inc.

      SC 13D/A - BigBear.ai Holdings, Inc. (0001836981) (Subject)

      12/10/24 4:15:32 PM ET
      $BBAI
      Computer Software: Prepackaged Software
      Technology